Drug Resistance, Neoplasm

JUL 27, 2026 · JOURNAL ARTICLE

Stress-specific 14-3-3-client modules in digestive cancers: an evidence-graded review of adaptive survival and therapy resistance.

Cancer Biology & Therapy

Narrative review synthesizing mechanistic evidence from functional studies in digestive cancers; no new primary data, clinical validation limited, and therapeutic translation not yet established.

JUL 20, 2026 · JOURNAL ARTICLE

Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin.

Cancer Biology & Therapy

In vitro study demonstrates reversal of cisplatin resistance in one cell line via ALDH and ABCC2 inhibition, requiring validation in additional models and clinical testing.

MAY 27, 2026 · JOURNAL ARTICLE

Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.

Drug Delivery

A comprehensive review article synthesizing mechanistic principles and design strategies for an emerging therapeutic modality (LYTACs) in preclinical and early translational stages, with no primary experimental data or clinical trial results.

MAY 26, 2026 · JOURNAL ARTICLE

Suppression of LncRNA AC008406.3 sensitizes breast cancer cells to docetaxel via triggering cuproptosis.

Cancer Biology & Therapy

In vitro and database study identifying lncRNA AC008406.3 as a cuproptosis regulator affecting docetaxel sensitivity in breast cancer cells, lacking clinical validation or human efficacy data.